Table 1

Characteristics of the included studies

Study	Location	Study design	Study quality assessment	Patients number (frequency male)	Devices number	Indication	Frequency tunnelled/ PORT	Frequency insertions open/ Percutaneous	Outcomes
Abbas et al 201410	Saudi Arabia	RC	Moderate	148 (74)	199	Haematological malignancy	101/47	NS	Duration
Adler et al 200611	Israel	PC	Moderate	281 (243)	419	Haematological and solid tumours	173/246	NS	Infection, mechanical, duration
Barrett et al 200422	UK	PC	Moderate	NS	824	Haematological and solid tumours	745/77	NS	Failure/removal
Basford et al 200325	Canada	RC	Moderate	67 (35)	98	Haematological and solid tumours	52/46	NS/41	Infection, mechanical
Beck et al 201926	Germany	RC	Moderate	296 (149)	NS	Haematological and solid tumours	168/128	NS	Infection, mechanical, thrombosis
Bratton et al 201327	USA	RC	Moderate	170 (NS)	144	Haematological and solid tumours	34/110	NS	Infection, mechanical, failure/removal
Chen et al 201628	Canada	RC	Serious	104 (53)	147	Haematological and solid tumours	40/70	NS	Thrombosis
Flynn et al 200329	USA	RC	Moderate	172 (96)	NS	Haematological and solid tumours	151/21	NS	Infection
Handrup et al 201030	Denmark	PC	Moderate	98 (96)	98	Haematological malignancy	63/35	NS	Infection
Hooda et al 200831	Pakistan	RC	Serious	92 (NS)	NS	Haematological malignancy	4/42	NS	Infection, acceptability
Hord et al 201612	USA	PC	Moderate	1113 (NS)	NS	Haematological and solid tumours	NS/NS	NS	Infection
Kelly et al 201313	USA	RC	Moderate	123 (68)	NS	Haematological and solid tumours	23/102	NS	Infection
La Quaglia et al 199214	USA	PC	Moderate	271 (149)	271	Haematological and solid tumours	229/42	NS	Infection, mechanical, failure/removal, duration
Mirro et al 198915	USA	PC	Moderate	264 (172)	286	Haematological and solid tumours	204/82	228/58	Infection, mechanical
Newman et al 201216	Israel	RC	Moderate	NS	328	Haematological and solid tumours	190/138	151/177	Infection
Park et al 202117	South Korea	RC	Moderate	470 (290)	NS	Haematological and solid tumours	226/242	NS	Infection
Pektas et al 201518	Turkey	RC	Moderate	106 (73)	203	Haematological malignancy	112/91	0/203	Infection, mechanical, thrombosis, failure/removal, duration, bleeding
Severien et al 199119	USA	RC	Moderate	60 (33)	75	Haematological malignancy	45/25	NS	Infection, mechanical
Stammers et al 201632	Canada	RC	Moderate	330 (152)	NS	Haematological and solid tumours	41/216	NS	Thrombosis
Wacker et al 199220	Switzerland	RC	Moderate	69 (45)	93	Haematological and solid tumours	59/34	56/37	Infection, thrombosis, duration
White et al 201221	UK	RC	Moderate	322 (165)	322	Haematological malignancy	68/254	NS	Infection, thrombosis, failure/removal, duration
Wurzel et al 198823	USA	PC	Moderate	62 (43)	78	Haematological and solid tumours	33/45	NS	Infection
Yacobovich et al 201524	Israel	RC	Moderate	262 (155)	463	Haematological and solid tumours	104/126	NS	Infection

NS, not specified; PC, prospective cohort study; PORT, implanted port; RC, retrospective cohort study.